As a pediatric pulmonologist, I care for patients with a wide range of lung and airway disorders. During my fellowship, the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator, ivacaftor, was released but was only effective in less than five percent of the CF population. Having such an effective treatment limited to a small subset of my patients was frustrating. This frustration led me to the lab of J.P. Clancy, a CF expert at Cincinnati Children's Hospital. Through working with Dr. Clancy, I began my current research path, with efforts to expand and optimize these therapies. Mutations in the CFTR gene cause CF, and there are more than 2,000 such mutations described to date. My research goal is to provide personalized, precise care to patients with rare CF genetic variants. I specifically work with patient-derived models of respiratory epithelia to model different functions of the CF airway. Through this work, my colleagues and I seek to maximize the potential benefits of CFTR modulator drugs by expanding access and aiding clinical therapeutic selection. We also seek to identify patient-specific factors that influence the severity of CF and the likelihood of therapeutic response.